Adstiladrin (nadofaragene firadenovec-vncg) / Ferring 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   177 News 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
ABLE-42, NCT06390111: A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

Withdrawn
4
25
US
nadofaragene firadenovec, Adstiladrin
Ferring Pharmaceuticals
Bladder Cancer, Ta/T1, CIS
07/26
07/26
rAd-IFN-CS-003, NCT02773849: ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Checkmark Approved for high-risk, non-muscle-invasive bladder cancer
Dec 2022 - Dec 2022: Approved for high-risk, non-muscle-invasive bladder cancer
Checkmark Data for the treatment of patients with high-grade BCG unresponsive NMIBC
Nov 2020 - Nov 2020: Data for the treatment of patients with high-grade BCG unresponsive NMIBC
Completed
3
157
US
ADSTILADRIN, rAd-IFN/SYN3NODA, INSTILADRIN
Ferring Pharmaceuticals, FKD Therapies Oy, Society of Urologic Oncology Clinical Trials Consortium
Superficial Bladder Cancer
05/19
05/23
INFINITE, NCT03710876 / 2017-003169-82: Efficacy & Safety of RAd-IFN Administered with Celecoxib & Gemcitabine in Patients with Malignant Pleural Mesothelioma

Active, not recruiting
3
53
Europe, Canada, US, RoW
rAd-IFN, Nadofaragene firadenovec, Celecoxib Oral Product, COX II Inhibitor, Gemcitabine, Chemotherapy
Ferring Ventures Limited, University of Pennsylvania
Malignant Pleural Mesothelioma
03/24
04/26
ABLE-32, NCT06510374: Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Recruiting
3
454
Canada, US
Nadofaragene Firadenovec, Adstiladrin
Ferring Pharmaceuticals
Intermediate Risk Non-Muscle Invasive Bladder Cancer
08/28
06/31
NCT05704244: Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects with High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting
3
25
Japan
FE 999326, nadofaragene firadenovec
Ferring Pharmaceuticals
Bladder Cancer
10/25
09/29
NCT06929286: A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Recruiting
3
125
US
Nadofaragene Firadenovec, Gemcitabine, Docetaxel
Memorial Sloan Kettering Cancer Center
Non-Muscle Invasive Bladder Cancer
04/28
04/28
ABLE-22, NCT06545955: A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Recruiting
2
150
US
Nadofaragene Firadenovec, ADSTILADRIN, Gemcitabine, Docetaxel, Pembrolizumab
Ferring Pharmaceuticals
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
07/26
07/28
LUNAR, NCT06668493: Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

Not yet recruiting
1/2
20
NA
Nadofaragene Firadenovec, Adstiladrin
Ferring Pharmaceuticals
Low-grade Upper Tract Urothelial Carcinoma
11/29
11/29
ABLE-41, NCT06026332: ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

Recruiting
N/A
400
US
ADSTILADRIN, Nadofaragene Firadenovec
Ferring Pharmaceuticals
Bladder Cancer
12/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
ABLE-42, NCT06390111: A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

Withdrawn
4
25
US
nadofaragene firadenovec, Adstiladrin
Ferring Pharmaceuticals
Bladder Cancer, Ta/T1, CIS
07/26
07/26
rAd-IFN-CS-003, NCT02773849: ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Checkmark Approved for high-risk, non-muscle-invasive bladder cancer
Dec 2022 - Dec 2022: Approved for high-risk, non-muscle-invasive bladder cancer
Checkmark Data for the treatment of patients with high-grade BCG unresponsive NMIBC
Nov 2020 - Nov 2020: Data for the treatment of patients with high-grade BCG unresponsive NMIBC
Completed
3
157
US
ADSTILADRIN, rAd-IFN/SYN3NODA, INSTILADRIN
Ferring Pharmaceuticals, FKD Therapies Oy, Society of Urologic Oncology Clinical Trials Consortium
Superficial Bladder Cancer
05/19
05/23
INFINITE, NCT03710876 / 2017-003169-82: Efficacy & Safety of RAd-IFN Administered with Celecoxib & Gemcitabine in Patients with Malignant Pleural Mesothelioma

Active, not recruiting
3
53
Europe, Canada, US, RoW
rAd-IFN, Nadofaragene firadenovec, Celecoxib Oral Product, COX II Inhibitor, Gemcitabine, Chemotherapy
Ferring Ventures Limited, University of Pennsylvania
Malignant Pleural Mesothelioma
03/24
04/26
ABLE-32, NCT06510374: Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Recruiting
3
454
Canada, US
Nadofaragene Firadenovec, Adstiladrin
Ferring Pharmaceuticals
Intermediate Risk Non-Muscle Invasive Bladder Cancer
08/28
06/31
NCT05704244: Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects with High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting
3
25
Japan
FE 999326, nadofaragene firadenovec
Ferring Pharmaceuticals
Bladder Cancer
10/25
09/29
NCT06929286: A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Recruiting
3
125
US
Nadofaragene Firadenovec, Gemcitabine, Docetaxel
Memorial Sloan Kettering Cancer Center
Non-Muscle Invasive Bladder Cancer
04/28
04/28
ABLE-22, NCT06545955: A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Recruiting
2
150
US
Nadofaragene Firadenovec, ADSTILADRIN, Gemcitabine, Docetaxel, Pembrolizumab
Ferring Pharmaceuticals
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
07/26
07/28
LUNAR, NCT06668493: Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

Not yet recruiting
1/2
20
NA
Nadofaragene Firadenovec, Adstiladrin
Ferring Pharmaceuticals
Low-grade Upper Tract Urothelial Carcinoma
11/29
11/29
ABLE-41, NCT06026332: ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

Recruiting
N/A
400
US
ADSTILADRIN, Nadofaragene Firadenovec
Ferring Pharmaceuticals
Bladder Cancer
12/25
12/25

Download Options